Larvol Delta - BioPath-Holdings-Outlines-Rationale-for-Development-of-BP1001A-as-Potential-Treatment-for-Obesity-in-Type-2-Diabetes-Patients

prexigebersen-A (BP1001-A) - Bio-Path

https://www.globenewswire.com/news-release/2024/12/11/2995241/0/en/Bio-Path-Holdings-Outlines-Rationale-for-Development-of-BP1001-A-as-Potential-Treatment-for-Obesity-in-Type-2-Diabetes-Patients.html

Dec 11, 2024

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next